StockData

ImmunityBio vs Immunocore

IBRX and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IBRX and IMCR compare

ImmunityBio is the larger company, worth 4.1 times as much as Immunocore ($6.4B against $1.5B).

ImmunityBio grew revenue faster over the last twelve months (121% versus 13.1% for Immunocore).

Immunocore keeps more of each dollar of sales as profit, with a net margin of −7.5% compared with −608% at ImmunityBio.

ImmunityBio scores higher on the StockData Score (8 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIBRXIMCR
Size and price
Market cap$6.4B$1.5B
Share price$6.02$29.94
Change, 1 year192%−15.2%
Change, 5 years−6.4%−21.4%
Beta (5Y)1.530.69
Employees691524
StockData Score
Total score8 (better)7
Valuation score01 (better)
Growth score22
Performance score13 (better)
Health score5 (better)1
Dividend score00
Valuation
P/S34.9×3.6× (better)
P/B–3.7×
FCF yield−4.7%−1.2% (better)
Fair value–$31.07
Margin of safety–3.6%
Growth
Revenue growth (TTM)121% (better)13.1%
Revenue growth, 5Y average185%–
Profitability
Gross margin98.8%98.9% (better)
Operating margin−150%−6.8% (better)
Net margin−608%−7.5% (better)
FCF margin−163%−4.2% (better)
Return on equity–−7.9%
Financial health
Interest coverage–−2.4×
Current ratio4.274.62 (better)
Altman Z-score−9.341.45 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Dividend yield–0.00%
Years of dividend growth–0
Shareholder yield0.00%0.00%
Ownership
Held by institutions19.1%102%
Held by insiders75.2%15.5%
Insider net buying, 12 months−$9.5M−$1.9M (better)
Short interest, % of float48.0%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.